Weight Loss Drug Users Report Altered Taste and Smell, Sparking Industry Interest

Individuals taking GLP-1 class weight loss medications are reporting significant changes in their senses of taste and smell, alongside appetite and weight reduction. These changes include beloved foods tasting different and even familiar perfumes smelling altered, leading to less enjoyment from eating. Preliminary research suggests a potential link to the medication, though the exact causes and the extent to which these sensory shifts contribute to reduced food intake remain unclear.

Professor Gal Dubnov-Raz, director of the Sports and Overweight Clinic for Children at Sheba Medical Center, noted that reports of altered perfume perception have emerged. "In the past two years, evidence has accumulated from several directions indicating a possible effect of these drugs on the senses of taste and smell," he stated. The fragrance industry, including companies like Givaudan and IFF, along with British perfumer CPL Aromas and cosmetics giant L'Oréal, are investigating this connection.

Some companies have observed increased interest in fragrances among users, hypothesizing they may be seeking alternative sources of sensory pleasure. Arno Gugenbiel, Global Marketing Director for Prestige Fragrance at Givaudan, shared that the company has been studying the link for about a year, finding that previously liked scents can become repulsive, while others become more appealing. Celine Manta from IFF indicated their research suggests GLP-1 users may develop a greater interest in smell as a source of enjoyment. The Global Brand President of L'Oréal Paris, Global Brand President of L'Oréal Paris, echoed this, suggesting users might be compensating for reduced food pleasure with other sensory gratifications, though this remains a hypothesis.

Pauline Joseph, Associate Director of the National Center for Smell and Taste at the U.S. National Institutes of Health, commented that the idea of these drugs affecting smell and taste is plausible. While the medications influence appetite, they may also impact the olfactory bulb tissue responsible for processing smells. However, she cautioned that it is too early to determine if and how this alters smell perception.

Research has explored these effects through various channels. Professor Dubnov-Raz cited social media discussions and spontaneous reports to the FDA's adverse event database, which have identified similar complaints about altered eating experiences. However, he stressed that such reports do not establish prevalence, necessitating further study.

A significant retrospective study published in JAMA Otolaryngology-Head & Neck Surgery compared over 438,000 type 2 diabetes patients treated with GLP-1 drugs to a similar group on other diabetes medications. Within two years, the GLP-1 group showed a 48% higher risk of a new diagnosis of taste or smell disorder, though the overall incidence remained low (less than 4 per 1,000). Smell disorders saw a more pronounced increase in risk (81%) compared to taste disorders (52%). The study's authors noted it was conducted on diabetes patients, not those using the drugs for obesity.

Another study in Physiology & Behavior involving 46 patients found a significant decrease in taste function across all basic tastes (sweet, salty, sour, bitter, umami) in 85% of participants, yet no corresponding decline in smell function was observed. Interestingly, less than a quarter of these participants self-reported a decrease in their sense of taste. Potential mechanisms include direct drug effects on brain taste pathways, altered central sensory processing, or indirect effects via appetite reduction.

Market research by NIQ in the U.S. indicated GLP-1 users spend 26% more on perfumes than average consumers, but this aligns with higher spending across most beauty categories, making it inconclusive regarding altered scent preferences. Professor Dubnov-Raz believes it is premature to develop specialized perfumes for GLP-1 users, citing the low prevalence of reported issues and the limitations of current research.